Tandem Diabetes Care stock hits 52-week low at $25.5

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) stock has reached a 52-week low, touching down at $25.5. With a market capitalization of $2.2 billion and current trading price of $24, this significant drop marks a notable moment for the medical device company, which specializes in insulin delivery systems. InvestingPro analysis indicates the stock is currently fairly valued, with analyst price targets ranging from $18 to $75. Despite this low, Tandem has experienced a 1-year change showing a 26.37% increase, with revenue growth of 10.75% and a beta of 1.32, indicating a volatile period for the stock but also highlighting a resilient upward trend over the past year. Investors are closely monitoring the company’s performance, as its innovative approach to diabetes management continues to evolve in a competitive healthcare market. InvestingPro subscribers have access to 8 additional key insights and a comprehensive Pro Research Report, essential for understanding TNDM’s full market position.

In other recent news, Tandem Diabetes Care reported a positive earnings surprise for the fourth quarter of 2024, with earnings per share (EPS) of $0.01, surpassing the forecasted -$0.21. The company’s revenue also exceeded expectations, reaching $282.65 million compared to the forecast of $251.3 million. Despite this strong financial performance, Citi analysts adjusted the price target for Tandem Diabetes Care shares to $35 from the previous $50, while maintaining a Buy rating, citing mixed results and forward-looking guidance concerns. Tandem’s fourth-quarter revenue of $252.4 million marked a 20.6% increase, exceeding the consensus estimate of $249.7 million, with international sales showing a significant 48.4% increase. However, the company’s 2025 revenue guidance of $997 million to $1.007 billion fell slightly below the consensus estimate of $1.01 billion, accounting for potential international headwinds. Tandem is focusing on expanding its market share in the Type 2 diabetes segment and enhancing its product offerings, with plans to integrate new technologies and expand its pharmacy channel. Despite these efforts, concerns linger over future profitability and competitive pressures in the market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.